Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia

  H&O  What is the mechanism of action for venetoclax, and why is it suited for chronic lymphocytic leukemia (CLL)? JS  Venetoclax (Venclexta, AbbVie/Genentech) has a […]